A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors
|Bellicum Pharmaceuticals, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / email@example.com
The purpose of this study is to test what dose of BPX-601 can be given safely with rimiducid to patients with certain types of cancer. The study will look for side effects (good and bad) and how your body responds to the treatment. The study will also see if the treatment helps to stop your cancer from growing or spreading. BPX-601 is a treatment made from your white blood cells (T cells). Your T cells are modified in a laboratory by adding a chimeric antigen receptor gene called a CAR. The CAR recognizes a tumor marker on your cancer. The addition of the CAR is thought to help your own T cells to find and attack your cancer.
This study is closed
Mark Stein, MD
|Are you 18 years of age or older?
|Are you fully active or at least able to carry out work of a light or sedentary nature?
|Do you have pancreatic ductal adenocarcinoma, gastric adenocarcinoma, or adenocarcinoma of the prostate?